Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Cemiplimab +/- Fianlimab in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07650266Phase 1Not yet recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
Phase 1, randomised trial in nasopharyngeal carcinoma (NPC) comparing Induction Therapy: Cemiplimab alone with Induction Therapy: Cemiplimab + Fianlimab (2 arms). Primary endpoint: Complete response rate at 4 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
cemiplimabfianlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07650266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650266.